General Internal Medicine

Cyclophosphamide

Questions discussed in this category

When would you consider using G-CSF in patients with rheumatic disease who have received cyclophosphamide?

2 Answers available

What is considered an adequate treatment period to assess response of AAV induction therapy with rituximab or cyclophosphamide?

1 Answer available

What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?

1 Answer available

Papers discussed in this category

Arthritis and rheumatism, 2010-01

Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

J. Rheumatol., 2019 Sep 01

Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.

Blood advances, 2024 Aug 13

Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.

Annals of oncology : official journal of the European Society for Medical Oncology, 2018 Sep 01

Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support.

J Rheumatol, 2006 Jul 01

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.

Journal of pharmacy practice, 2021 Nov 08

Use of Colony-Stimulating Factors in Patients With Systemic Lupus Erythematosus.

Related Topics in General Internal Medicine